How is Abbott Laboratories (ABT) doing?

Abbott Laboratories is a company in the medical, devices industry, based in Abbott Park, IL, worth $172.3B. Here is how its shares and business compare with the rest of the market, and where it shows up on our dashboards.

Updated Oct 9, 2026

P3 score

Weak

Abbott Laboratories shares are down 26% over the past year, 36 points behind the S&P 500. Its type is Falling Knife. Among large US stocks and funds it ranks in the 11th percentile on market beat, the 45th on staying power and the 49th on business growth. It appears on 6 of our dashboards.

$99.60−26% in a yearWorth $172.3B

Compare with DHR · BDX · MDT · TMO · DXCM · BSX · EW · JNJ · PODD

Financials, earnings and news on Stox ›

Past year

The past year

Price against the S&P 500, each set to $100 a year ago. Score is its weekly rank against the market. Select a tile for that score month by month.

ABT against the S&P 500, past year

$100 a year ago. Abbott Laboratories −26%, the S&P 500 +16%.

ABTS&P 500

What kind of stock is it?

Its type on Stox Atlas, from its four scores: beating or lagging the market, a steady or erratic rank, a growing or slowing business, and whether buyers or sellers lead.

Falling Knife

LaggingErraticSlowingBought

Lagging erratically on a soft business, with buyers trying to catch it.

NovDecJanFebMarAprMayJunJulAugSepNow

Falling Knife this month; Turning Up before that.

Also Falling Knife (55 in all): MDT · BMRN · DHR · UHS · QGEN · CDNS

EmbracedToppingAccumulatingRejectedStable rankBellwetherDistribution TopCoiled SpringWallflowerHolding rankFaith TradeRolling OverBottom FishedSleepy StapleUnsteady rankHot HandChurning WinnerTurning UpShow-Me GrowerBouncy rankSpeculative PopExhausted RallyFalling KnifeBroken Year

How is it doing against its group?

Its group is Health care, 86 large US stocks and funds whose prices tend to move together. Tools, biotech and large-cap pharma — defensive growth.

ABT, past year−26%76 of 86 in the group

Rest of the group+21%equal-weighted

S&P 500+16%past year

Abbott Laboratories is −26% over the past year, against +21% for the rest of the group and +16% for the S&P 500. It ranks 76th of 86 in Health care.

ABTRest of the group

Best in the groupRVMD Revolution Medicines+297%ILMN Illumina+184%NTRA Natera+133%

Worst in the groupPODD Insulet−57%BSX Boston Scientific−56%RARE Ultragenyx−50%

Its closest rivalsDHR Danaher+7%BDX Becton Dickinson+21%MDT Medtronic−10%TMO Thermo Fisher Scientific+23%DXCM Dexcom+24%

Health care on Stox ›

How much does it move?

Its typical daily move, against its own past year, the market and other large stocks. Swings describe risk, not direction.

About usual Abbott Laboratories typically moves 2.3% in a day, about usual for it, and it swings less than 82% of large US stocks.

Typical day2.3%about $2.33 a share

Its usual2.3%about usual, 1.0× its year’s average

Against the S&P 5002.1×the index’s typical day is 1.1%

Unusual day±4.7%twice its typical day

Deepest fall, past year−39%now 26% below its high

In the S&P’s down weeks11%of the index’s fall, three years; beta 0.2

Typical daily move (ATR)Its year’s average 2.32%

ABT on our dashboards

Every question where Abbott Laboratories appears, in the order of the home page, with its reading and place in that table. Select a question to open it with ABT highlighted. Select a column to sort.

Question	Reading	Place	Details
Which stocks are analysts upgrading and downgrading? Events	1Upgraded	9 of 60	Upgrades 1 · Downgrades 0 · Latest change Rothschild & Co: Neutral to Buy, Oct 2
Who reports next, and what is expected? Earnings	51Steady	62 of 106	Estimate change, 1M 0% · Expected EPS growth +8% · Stock vs S&P, 1M −6.4 pts
Is the market rewarding earnings beats? Earnings	–Beat	36 of 60	Surprise +2% · Move vs S&P +14.3% · Reported 2026-07-16
Which stocks keep losing? Leading stocks	9131 of 52 wks	48 of 60	vs S&P, 1Y −41 pts
What is Congress trading? Who’s buying and selling	3Sold	27 of 60	Buying 0 · Selling 3
Where is money flowing in? Who’s buying and selling	92Inflow	39 of 60	30 days 41 · 5 days 33 · Net buying +13%

Go deeper on Stox

ABT’s full profile: financial statements, earnings and analysts’ estimates, valuation against its sector, recent news with a summary, and its scores in detail.

Open ABT on Stox ›All 16 types on Atlas ›Its group on Stox ›

How to read this page

How it’s measured. Scores from Stox rank the stock against about 1,200 S&P 500, Nasdaq-100 and Russell 1000 stocks and popular funds, where 100 is best; market beat and staying power use prices, business growth uses revenue, margins and cash flow. Readings on other dashboards come from this site’s pages.

Sources. Daily prices and company financial statements from Financial Modeling Prep; scores and co-movement groups from Stox.

Scores are percentiles: 80 means the stock ranks above 80% of the others on that measure. They describe the recent past and are not advice or a forecast.

Its type follows Stox Atlas: each of the four scores is split at 50. “Steady” means its rank has held, high or low, so it says nothing on its own about direction.

Its group is the cluster of large US stocks whose prices have moved together over five years, with the market’s own moves taken out. The typical daily move is the average true range over 14 days, a measure of how far the price travels in a day including overnight gaps.

For financial statements, earnings and news, see ABT’s full profile on Stox.

This page is information, not investment advice. About our data and methods ›

Full profile on Stox ›Health care stocks ›DHR · Danaher ›BDX · Becton Dickinson ›MDT · Medtronic ›TMO · Thermo Fisher Scientific ›